EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of 18F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis

Steven G Allen, Benjamin S Rosen, Madhava Aryal, Yue Cao, Matthew J Schipper, Ka Kit Wong, Keith A Casper, Steven B Chinn, Kelly M Malloy, Mark E Prince, Andrew J Rosko, Andrew G Shuman und 9 weitere

International Journal of Radiation Oncology*Biology*Physics · 2023

DOI: 10.1016/j.ijrobp.2023.03.043 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023. Verfasst von Steven G Allen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, University of Michigan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) parameters are prognostic of oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma (OPSCC). We used FDG-PET imaging biomarkers to select patients for de-escalated chemoradiotherapy (CRT), hypothesizing that acute toxicity will be improved with de-escalation. METHODS AND MATERIALS: This is a planned interim initial feasibility and acute toxicity report from a phase 2, prospective, nonrandomized study, which enrolled patients with stage I-II p16+ OPSCC. All patients started definitive CRT to 70 Gy in 35 fractions, and those who met de-escalation criteria on midtreatment FDG-PET at fraction 10 completed treatment at 54 Gy in 27 fractions. We report the acute toxicity and patient-reported outcomes for 59 patients with a minimum follow-up of 3 months. RESULTS: There were no statistically significant differences between baseline patient characteristics in the standard and de-escalated cohorts. There were 28 of 59 (47.5%) patients who met FDG-PET de-escalation criteria and collectively received 20% to 30% less dose to critical organs at risk known to affect toxicity. At 3 months posttreatment, patients who received de-escalated CRT lost significantly less weight (median, 5.8% vs 13.0%; P < .001), had significantly less change from baseline in penetration-aspiration scale score (median, 0 vs 1; P = .018), and had significantly fewer aspiration events on repeat swallow study (8.0% vs 33.3%, P = .037) compared with patients receiving standard CRT. CONCLUSIONS: Approximately half of patients with early-stage p16+ OPSCC are selected for de-escalation of definitive CRT using midtreatment FDG-PET biomarkers, which resulted in significantly improved rates of observed acute toxicity. Further follow-up is ongoing and will be required to determine whether this de-escalation approach preserves the favorable oncologic outcomes for patients with p16+ OPSCC before adoption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsHead and Neck NeoplasmsHumansFluorodeoxyglucose F18Feasibility StudiesProspective StudiesPositron-Emission TomographyChemoradiotherapySquamous Cell Carcinoma of Head and Neck

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
  • Department of Biostatistics, University of Michigan, Ann Arbor, Michigan.
  • Department of Radiology, University of Michigan, Ann Arbor, Michigan.
  • Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
  • Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan; Surgery Services-ENT Section, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Department of Internal Medicine, Division of Medical Oncology, University of Michigan, Ann Arbor, Michigan.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • University of Michigan
  • National Institutes of Health
  • Rogel Cancer Center, University of Michigan

Zitieren

APA

Allen, S. G., Rosen, B. S., Aryal, M., Cao, Y., Schipper, M. J., Wong, K. K., Casper, K. A., Chinn, S. B., Malloy, K. M., Prince, M. E., Rosko, A. J., Shuman, A. G., Spector, M. E., Stucken, C. L., Swiecicki, P. L., Worden, F. P., Brenner, J. C., Schonewolf, C. A., Elliott, D. A., …, & Shah, J. L. (2023). Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of 18F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.03.043

Vancouver

Allen SG, Rosen BS, Aryal M, Cao Y, Schipper MJ, Wong KK, et al. Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of 18F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis. International Journal of Radiation Oncology*Biology*Physics. 2023. doi:10.1016/j.ijrobp.2023.03.043

BibTeX
@article{Allen2023,
  author = {Allen, Steven G and Rosen, Benjamin S and Aryal, Madhava and Cao, Yue and Schipper, Matthew J and Wong, Ka Kit and Casper, Keith A and Chinn, Steven B and Malloy, Kelly M and Prince, Mark E and Rosko, Andrew J and Shuman, Andrew G and Spector, Matthew E and Stucken, Chaz L and Swiecicki, Paul L and Worden, Francis P and Brenner, J Chad and Schonewolf, Caitlin A and Elliott, David A and Mierzwa, Michelle L and Shah, Jennifer L},
  title = {Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of 18F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2023},
  doi = {10.1016/j.ijrobp.2023.03.043}
}
Kostenlos starten →